HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+1.1%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$800M
AUM Growth
+$800M
(-18%)
Cap. Flow
-$190M
Cap. Flow
% of AUM
-23.8%
Top 10 Holdings %
Top 10 Hldgs %
45.64%
Holding
74
New
18
Increased
11
Reduced
22
Closed
14
Top Buys
| 1 |
AbbVie
ABBV
|
$41.6M |
| 2 |
Thermo Fisher Scientific
TMO
|
$26M |
| 3 |
Agilent Technologies
A
|
$24.3M |
| 4 |
Amgen
AMGN
|
$17M |
| 5 |
DexCom
DXCM
|
$14.4M |
Top Sells
| 1 |
Biogen
BIIB
|
$91.8M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$41.7M |
| 3 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$36.5M |
| 4 |
Natera
NTRA
|
$36.5M |
| 5 |
Boston Scientific
BSX
|
$32.9M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioMarin Pharmaceuticals
BMRN
$11.3B
| $64.3M | 8.05% |
759,038
+18,090
| +2% | +$1.53M |
|
|
2
AbbVie
ABBV
$373B
| $41.6M | 5.21% |
+310,250
| New | +$41.6M |
|
|
3
Agilent Technologies
A
$35.2B
| $41.1M | 5.14% |
338,030
+199,750
| +144% | +$24.3M |
|
|
4
Boston Scientific
BSX
$158B
| $37.1M | 4.64% |
958,600
-849,390
| -47% | -$32.9M |
|
5
Eli Lilly
LLY
$657B
| $33.4M | 4.17% |
103,150
+32,520
| +46% | +$10.5M |
|
6
Cencora
COR
$57.2B
| $32.4M | 4.05% |
239,150
+82,240
| +52% | +$11.1M |
|
7
UnitedHealth
UNH
$280B
| $31.8M | 3.98% |
62,980
-5,250
| -8% | -$2.65M |
|
8
Danaher
DHR
$145B
| $30.4M | 3.81% |
117,800
+20,920
| +22% | +$5.4M |
|
9
Tenet Healthcare
THC
$16.3B
| $26.8M | 3.35% |
518,990
| – | – |
|
|
10
Thermo Fisher Scientific
TMO
$183B
| $26M | 3.25% |
+51,240
| New | +$26M |
|
11
Centene
CNC
$14.5B
| $23.4M | 2.93% |
300,970
-239,890
| -44% | -$18.7M |
|
12
Cigna
CI
$80.3B
| $21.3M | 2.67% |
76,910
-19,560
| -20% | -$5.43M |
|
13
Cytokinetics
CYTK
$5.94B
| $21.1M | 2.63% |
434,560
-51,040
| -11% | -$2.47M |
|
14
Humana
HUM
$37B
| $20.8M | 2.6% |
42,920
-4,300
| -9% | -$2.09M |
|
15
Syndax Pharmaceuticals
SNDX
$1.39B
| $20.6M | 2.58% |
859,240
-64,160
| -7% | -$1.54M |
|
|
16
DexCom
DXCM
$29.1B
| $20.4M | 2.55% |
253,500
+178,720
| +239% | +$14.4M |
|
|
17
Biogen
BIIB
$20.2B
| $18.7M | 2.34% |
69,950
-343,690
| -83% | -$91.8M |
|
18
Elevance Health
ELV
$72.2B
| $17.7M | 2.21% |
38,910
-15,320
| -28% | -$6.96M |
|
|
19
Amgen
AMGN
$154B
| $17M | 2.12% |
+75,370
| New | +$17M |
|
20
LivaNova
LIVN
$3.09B
| $16.7M | 2.08% |
328,030
-158,520
| -33% | -$8.05M |
|
21
Henry Schein
HSIC
$8.29B
| $16.4M | 2.05% |
248,920
| – | – |
|
22
Bristol-Myers Squibb
BMY
$96.1B
| $15.9M | 1.98% |
223,150
-189,270
| -46% | -$13.5M |
|
23
Incyte
INCY
$16.9B
| $15.2M | 1.9% |
227,851
-6,279
| -3% | -$418K |
|
|
HZNP
24
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $14.2M | 1.78% |
229,530
-674,320
| -75% | -$41.7M |
|
25
Becton Dickinson
BDX
$54.1B
| $14M | 1.75% |
62,930
+7,220
| +13% | +$1.61M |
|